Literature DB >> 31372723

Non-muscle invasive bladder cancer (NMIBC): boiling arena and promissory future.

Leonardo O Reis1,2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31372723     DOI： 10.1007/s00345-019-02894-5

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  9 in total

Review 1.  Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC).

Authors:  Ryan P Werntz; Brittany Adamic; Gary D Steinberg
Journal:  World J Urol       Date:  2018-12-04       Impact factor: 4.226

2.  Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC).

Authors:  Jean Carlo F Datovo; Wilmar Azal Neto; Gustavo B Mendonça; Danilo L Andrade; Leonardo O Reis
Journal:  World J Urol       Date:  2019-02-25       Impact factor: 4.226

3.  Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.

Authors:  Mohit Gupta; Niv Milbar; Giorgia Tema; Filippo Pederzoli; Meera Chappidi; Max Kates; Christopher J VandenBussche; Trinity J Bivalacqua
Journal:  World J Urol       Date:  2019-01-23       Impact factor: 4.226

4.  Mutations in CDKN2A and the FGFR3 genes on bladder cancer diagnosis: a systematic review and meta-analysis.

Authors:  Herney Andrés García-Perdomo; Juan Pablo Usubillaga-Velasquez; James Alejandro Zapata-Copete; Leonardo Oliveira Reis
Journal:  World J Urol       Date:  2019-04-27       Impact factor: 4.226

Review 5.  The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside.

Authors:  Jonathan J Duplisea; Sharada Mokkapati; Devin Plote; Kimberly S Schluns; David J McConkey; Seppo Yla-Herttuala; Nigel R Parker; Colin P Dinney
Journal:  World J Urol       Date:  2018-11-11       Impact factor: 4.226

Review 6.  Diagnostic biomarkers in non-muscle invasive bladder cancer.

Authors:  Izak Faiena; Charles J Rosser; Karim Chamie; Hideki Furuya
Journal:  World J Urol       Date:  2018-11-22       Impact factor: 4.226

7.  Moreau Strain Bacillus Calmette-Guérin Low Versus Standard Dose in the Treatment of High-Grade T1 Bladder Cancer: A Retrospective Observational Cohort Study.

Authors:  Bruno D B Carneiro; Brunno C F Sanches; Danilo L Andrade; Brunno R I Voris; Leonardo O Reis
Journal:  Clin Genitourin Cancer       Date:  2019-04-16       Impact factor: 2.872

8.  Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories.

Authors:  Matthew Mossanen; Ye Wang; Julie Szymaniak; Wei Shen Tan; Melissa J Huynh; Mark A Preston; Quoc-Dien Trinh; Guru Sonpavde; Adam S Kibel; Steven L Chang
Journal:  World J Urol       Date:  2018-11-16       Impact factor: 4.226

Review 9.  Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.

Authors:  Charles C Peyton; Juan Chipollini; Mounsif Azizi; Ashish M Kamat; Scott M Gilbert; Phillippe E Spiess
Journal:  World J Urol       Date:  2018-12-07       Impact factor: 3.661
  9 in total
  2 in total

1.  Non-muscle invasive bladder cancer cystoscopic surveillance: from overuse to underuse and non-adherence impact.

Authors:  Leonardo O Reis
Journal:  Transl Androl Urol       Date:  2019-12

2.  Boosting bladder cancer treatment by intravesical nitazoxanide and bacillus calmette-guérin association.

Authors:  Isis G A Kiehl; Eduardo Riccetto; Ana C C Salustiano; Marina V Ossick; Karen L Ferrari; Heloisa B Assalin; Osamu Ikari; Leonardo O Reis
Journal:  World J Urol       Date:  2020-06-02       Impact factor: 4.226
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.